Sai Life Sciences Ltd
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
- Market Cap ₹ 23,759 Cr.
- Current Price ₹ 1,120
- High / Low ₹ 1,149 / 704
- Stock P/E 66.9
- Book Value ₹ 117
- Dividend Yield 0.00 %
- ROCE 19.6 %
- ROE 15.4 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 42.2% CAGR over last 5 years
Cons
- Stock is trading at 9.60 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.7% over last 3 years.
- Working capital days have increased from 51.8 days to 77.6 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,192 | |
| 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,561 | |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 631 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 29% |
| 6 | 18 | 27 | 28 | 27 | 29 | 35 | 41 | |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 39 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 167 |
| Profit before tax | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 466 |
| Tax % | 35% | 30% | 25% | 36% | 39% | 24% | 25% | 25% |
| 73 | 76 | 61 | 6 | 10 | 83 | 170 | 349 | |
| EPS in Rs | 8.16 | 16.48 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 1,117% | 676% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 22% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 226% |
| TTM: | 107% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 54% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 13% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,463 |
| 249 | 304 | 637 | 752 | 933 | 928 | 352 | 288 | |
| 247 | 312 | 318 | 527 | 358 | 359 | 665 | 854 | |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,626 |
| 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,815 | |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 270 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 50 |
| 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,490 | |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,626 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 129 | 116 | -36 | 105 | 219 | 263 | 314 | ||
| -158 | -262 | -260 | -102 | -99 | -191 | -536 | ||
| 268 | -4 | 296 | 72 | -201 | -95 | 301 | ||
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 | |
| Free Cash Flow | -28 | -157 | -298 | -102 | 148 | 82 | -55 | |
| CFO/OP | 90% | 81% | -13% | 90% | 132% | 96% | 82% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 99 | 102 | 85 | 64 | 76 | 62 |
| Inventory Days | 86 | 79 | 127 | 179 | 121 | 72 | 93 | 97 |
| Days Payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 | 182 |
| Cash Conversion Cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 | -24 |
| Working Capital Days | 55 | 24 | 62 | 42 | 36 | 12 | 66 | 78 |
| ROCE % | 13% | 9% | 3% | 6% | 11% | 14% | 20% |
Insights
In beta| Mar 2009 | Mar 2011 | Mar 2013 | Mar 2017 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Installed Reactor Capacity KL |
|
||||||||
| Active Customers (Innovators) Number |
|||||||||
| Capacity Utilization (Average) % |
|||||||||
| Commercial Molecules (CDMO) Number |
|||||||||
| Molecules in Phase III / Pre-registration Number |
|||||||||
| Headcount - Scientists Number |
|||||||||
| Product Development Pipeline (Early-Phase) Number |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 May - Newspaper publication for the Audited Financial Results for the quarter and year ended 31 March 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
15 May - Sai Life Sciences uploaded Q4/FY26 audited results earnings call recording on 15 May 2026.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
15 May - Allotment of 92,000 Equity Shares under ESOP Schemes of the Company.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
15 May - CRISIL monitoring report for quarter ended 31 March 2026 shows IPO proceeds fully utilized, no deviations.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
15 May - Investor Presentation for the quarter and year ended 31 March 2026.
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptPPT REC
Business Profile[1]
Sai Life Sciences is an integrated CRDMO (Contract Research, Development and Manufacturing Organization) delivering end-to-end services across the pharmaceutical lifecycle from early drug discovery to commercial manufacturing.